Patents Examined by Eileen O'Hara
  • Patent number: 7307153
    Abstract: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: December 11, 2007
    Assignee: Genentech, Inc.
    Inventors: Sherman Fong, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, Daniel Tumas, Colin K. Watanabe, William I. Wood, Zemin Zhang
  • Patent number: 7304140
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: December 4, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
  • Patent number: 7304141
    Abstract: The present invention provides novel polynucleotides encoding HLRRBM1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRBM1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly immune diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: April 15, 2005
    Date of Patent: December 4, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: John N. Feder, Chandra S. Ramanathan, Gabriel A. Mintier, David Bol
  • Patent number: 7285636
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: October 23, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • Patent number: 7285644
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: October 23, 2007
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Maureen Beresini, Laura DeForge, Luc Desnoyers, Ellen Filvaroff, Wei-Qiang Gao, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Steven Sherwood, Victoria Smith, Timothy A. Stewart, Daniel Tumas, Colin K. Watanabe, William I. Wood, Zemin Zhang
  • Patent number: 7282352
    Abstract: The present invention relates to a method for improving homogeneity and/or secretion of a recombinant protein of interest expressed in mammalian cells by replacing the endogenous signal peptide sequence of the DNA encoding the protein of interest with that of human hGH. Specifically, the present invention relates to a method wherein the protein of interest is a subunit of the follicle stimulating hormone (FSH). The invention also relates to DNA expression vectors containing the sequence encoding such proteins of interest fused to the signal peptide sequence of the hGH and to cells harbouring such vectors.
    Type: Grant
    Filed: June 2, 2004
    Date of Patent: October 16, 2007
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Edith Chitlaru, Hagit Amitai, Daniel Helman
  • Patent number: 7271248
    Abstract: Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: September 18, 2007
    Assignee: Schering Corporation
    Inventors: Gerard T. Hardiman, Fernando L. Rock, J. Fernando Bazan, Robert A. Kastelein, Stephen W. K. Ho, Yong-Jun Liu
  • Patent number: 7267964
    Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Dermacentor variabilis ligand gated ion channel proteins. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding D. variabilis LGIC/GluCl channels, substantially purified forms of associated D. variabilis channel proteins and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Dermacentor variabilis LGIC/GluCl, which will be useful as insecticides and acaracides.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: September 11, 2007
    Assignee: Merial Limited
    Inventors: Doris F. Cully, Yingcong Zheng
  • Patent number: 7267820
    Abstract: There is disclosed a method for diagnosing neurotransmission or developmental disorders in a mammal comprising the step of detecting in a bodily fluid of said mammal autoantibodies to an epitope of the muscle specific tyrosine kinase (MuSK). One such method comprises a) contacting said bodily fluid with said MuSK or an antigenic determinant thereof; and b) detecting any antibody-antigen complexes formed between said receptor tyrosine kinase or an antigenic fragment thereof and antibodies present in said bodily fluid, wherein the presence of said complexes is indicative of said mammal suffering from said neurotransmission or developmental disorders. Also disclosed are kits for use in the diagnosis of neurotransmission and subsequent developmental disorders.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: September 11, 2007
    Assignees: Isis Innovation Limited, Max-Planck Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Angela Vincent, Werner Hoch
  • Patent number: 7268217
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 2, 2002
    Date of Patent: September 11, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
  • Patent number: 7261894
    Abstract: The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, the use of such polypeptides in cellular and immune reactions, the use of such polypeptides in screening for agonists or antagonists of IL-1 epsilon activity, and kits comprising such polypeptides.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: August 28, 2007
    Assignee: Immunex Corporation
    Inventors: John E Sims, Dirk E Smith
  • Patent number: 7256007
    Abstract: The present invention relates generally to a method for regulating cytokine signaling and agents useful for same. The method of the present invention is predicated in part on the identification of the molecular target of suppressor of cytokine signaling (SOCS) interaction in controlling cytokine signaling. The identification of the molecular target permits the development of assays to screen for a range of agonists and antagonists useful in modulating cytokine function. The present invention further provides, therefore, screening assays and more particularly high through-put screening assays for agonists and antagonists of SOCS-receptor interaction. Such agonists and antagonists are useful in the manufacture of medicaments for controlling cytokine signaling. Control of cytokine signaling is important for the treatment of a range of conditions including cancer, inflammatory conditions, immunological disorders and any other conditions involving aberrations of signal transduction.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: August 14, 2007
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Sandra Elaine Nicholson, Manuel Baca, Nicos A. Nicola, Douglas Hilton, Jian Guo Zhang, Louis Fabri, Andrew Nash
  • Patent number: 7229965
    Abstract: The invention relates to treatment of patients in need of increasing insulin sensitivity by administration of growth hormone or analogues thereof, preferably human growth hormone, in a low dose and the use of growth hormone or analogues thereof, preferably human growth hormone, for the manufacturing of a medicament useful for increasing insulin sensitivity in low dose therapy. The patient is preferably a normal subject, i.e. not growth hormone deficient patient and/or a non-obese patients. By low dose therapy is preferably meant less than 0.008 mg/kg/day, preferably 0.007 mg/kg/day or less, more preferably 0.005 mg/kg/day or less and most preferably 0.003 mg/kg/day or less. The therapy is preferably performed during short term treatment, preferably less than one month.
    Type: Grant
    Filed: January 21, 2004
    Date of Patent: June 12, 2007
    Assignee: Pharmacia AB
    Inventor: David B Dunger
  • Patent number: 7226591
    Abstract: The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: September 10, 2002
    Date of Patent: June 5, 2007
    Assignee: Genentech, Inc.
    Inventors: Austin L. Gurney, Sudeepta Aggarwal, Ming-Hong Xie, Ellen M. Maruoka, Jessica S. Foster, Audrey Goddard, William I. Wood
  • Patent number: 7223558
    Abstract: The present invention provides novel polynucleotides encoding BGS-2, 3, and 4 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-2, 3, and 4 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: July 11, 2002
    Date of Patent: May 29, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Shujian Wu, Stanley R. Krystek, Liana Lee, John N. Feder, Janet D. Cheng
  • Patent number: 7220722
    Abstract: Methods and pharmaceutical compositions useful for treating obesity-related disorders using ApM-1 and related proteins.
    Type: Grant
    Filed: February 5, 2002
    Date of Patent: May 22, 2007
    Assignee: Serono Genetics Institute S.A.
    Inventors: Bernard Bihain, Lydie Bougueleret, Frances Yen-Potin
  • Patent number: 7205108
    Abstract: The present invention relates to gene expression in normal cells and cells of malignant tumors and particularly to novel markers associated with cancer, Trp8, Trp9 and Trp10, and the genes encoding Trp8, Trp9 and Trp10. Also provided are vectors, host cells, antibodies, and recombinant methods for producing these human proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating a tumor.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: April 17, 2007
    Inventor: Ulrich Wissenbach
  • Patent number: 7201896
    Abstract: The invention relates to the use of IL6RIL6 chimera in the treatment and prevention of neurological diseases and disorders.
    Type: Grant
    Filed: June 21, 2000
    Date of Patent: April 10, 2007
    Assignees: Yeda Research and Development Company Ltd., Applied Research Systems ARS Holding N.V.
    Inventors: Michel Revel, Judith Chebath, Marina Pizzi, PierFranco Spano, Ursula Boschert
  • Patent number: 7198914
    Abstract: The present inventors conducted a similarity search of the amino acid sequence of known G protein-coupled receptor proteins in GenBank, and obtained a novel human GPCR gene “BG37”. cDNA containing the ORF of the gene was cloned and its nucleotide sequence was determined. Moreover, novel GPCR “BG37” genes from mouse and rat were isolated. Use of the novel GPCR of the present invention enables screening of ligands, compounds inhibiting the binding to a ligand, and candidate compounds of pharmaceuticals which can regulate signal transduction from the “BG37” receptor.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: April 3, 2007
    Assignee: Banyu Pharmaceutical Co., Ltd.
    Inventors: Takaharu Maruyama, Takao Nakamura, Hiraku Itadani, Ken-Ichi Tanaka
  • Patent number: 7196055
    Abstract: Methods to control, or manipulate, melanocyte and keratinocyte cell death are disclosed. In particular, a method of preventing epidermal melanocyte cell loss due to injury in a vertebrate is disclosed. Also disclosed is a method of inducing hair growth in a vertebrate, a method of inducing hair color in a vertebrate, a method of inducing skin color in a vertebrate, a method of treating baldness in an individual, and a method of treating alopecia areata in an individual.
    Type: Grant
    Filed: February 4, 1998
    Date of Patent: March 27, 2007
    Assignee: Trustees of Boston University
    Inventors: Barbara A. Gilchrest, Mina Yaar, Mark S. Eller